Navidea Biopharmaceuticals Inc Buchwert je Aktie
Was ist das Buchwert je Aktie von Navidea Biopharmaceuticals Inc?
Buchwert je Aktie von Navidea Biopharmaceuticals Inc ist -0.03
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Navidea Biopharmaceuticals Inc
Was macht Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Unternehmen mit buchwert je aktie ähnlich Navidea Biopharmaceuticals Inc
- FarmaForce hat Buchwert je Aktie von -0.03
- Newtopia hat Buchwert je Aktie von -0.03
- Curzon Plc hat Buchwert je Aktie von -0.03
- Amarillo Biosciences hat Buchwert je Aktie von -0.03
- Alkaline Water Inc hat Buchwert je Aktie von -0.03
- Body & Mind hat Buchwert je Aktie von -0.03
- Navidea Biopharmaceuticals Inc hat Buchwert je Aktie von -0.03
- Lavide NV hat Buchwert je Aktie von -0.03
- MedMira hat Buchwert je Aktie von -0.03
- Thin Film Electronics ASA hat Buchwert je Aktie von -0.03
- Jayex Healthcare hat Buchwert je Aktie von -0.03
- Boomer hat Buchwert je Aktie von -0.03
- Chilean Metals hat Buchwert je Aktie von -0.03